Alibaba
BABA
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
Apple
AAPL
US Stock MarketDetailed Quotes
AKBA Akebia Therapeutics
- 2.1300
- -0.0100-0.47%
Close Feb 14 16:00 ET
- 2.1109
- -0.0191-0.90%
Post 20:01 ET
464.73MMarket Cap-9.68P/E (TTM)
2.1700High2.1100Low1.31MVolume2.1300Open2.1400Pre Close2.79MTurnover0.66%Turnover RatioLossP/E (Static)218.18MShares2.480052wk High-9.22P/B421.63MFloat Cap0.800052wk Low--Dividend TTM197.95MShs Float31.0000Historical High--Div YieldTTM2.80%Amplitude0.2410Historical Low2.1330Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Akebia Therapeutics Stock Forum
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards ...
Akebia Therapeutics Announces Multiple Positive Business Updates
Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.
Market research indicates strong physician interest, with 99% of n...
Benzinga· 2 mins ago
New Commercial Supply Contracts for Vafseo (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S.
Vafseo tablets now shipping in the U.S.
Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo...
No comment yet